Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

@article{Wu2008AssociationBI,
  title={Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.},
  author={Ji Yuan Wu and Feng Meng and Ling-yuan Kong and Zhenghong Peng and Yunming Ying and William G. Bornmann and Bryant G. Darnay and Betty Lamothe and Hanshi Sun Sun and Moshe Talpaz and Nicholas J. Donato},
  journal={Journal of the National Cancer Institute},
  year={2008},
  volume={100 13},
  pages={
          926-39
        }
}
BACKGROUND Imatinib is a tyrosine kinase inhibitor that is used to treat chronic myelogenous leukemia (CML). BCR-ABL mutations are associated with failure of imatinib treatment in many CML patients. LYN kinase regulates survival and responsiveness of CML cells to inhibition of BCR-ABL kinase, and differences in LYN regulation have been found between imatinib-sensitive and -resistant CML cell lines. METHODS We evaluated cells from 12 imatinib-resistant CML patients with mutation-negative BCR… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 81 CITATIONS

FILTER CITATIONS BY YEAR

2007
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations

  • Averaged 5 Citations per year over the last 3 years

  • 11% Increase in citations per year in 2018 over 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 57 REFERENCES

TAK 1 - dependent signaling requires functional interaction with TAB 2 / TAB 3

A Besse, B Lamothe, AD Campos
  • J Biol Chem
  • 2007

Gene expression changes associated with progression and response in chronic myeloid leukemia.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2006

Similar Papers

Loading similar papers…